RPL6P27: A Potential Drug Target and Biomarker (G645387)

Target Name: RPL6P27

NCBI ID: G645387

RPL6P27

Other Name(s): RPL6_10_1582 | Ribosomal protein L6 pseudogene 27 | ribosomal protein L6 pseudogene 27

RPL6P27: A Potential Drug Target and Biomarker

RPL6P27 (RPL6_10_1582) is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. It is a member of the P27 family of proteins, which are involved in the regulation of DNA replication, cell division, and apoptosis. The P27 family of proteins are known to play a crucial role in the development and maintenance of normal cellular processes, and the dysfunction of these proteins has been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

The RPL6P27 protein is of particular interest as a potential drug target or biomarker because of its involvement in the regulation of cell division and its potential to interact with a variety of signaling pathways. Several studies have suggested that RPL6P27 may be involved in the regulation of cell proliferation, and that it may interact with signaling pathways that are involved in cell growth, differentiation, and survival. Additionally, RPL6P27 has been shown to be involved in the regulation of apoptosis, which is a critical process that helps cells eliminate themselves when they are no longer needed.

Drug Target Potential

RPL6P27 is a protein that has been shown to interact with a variety of signaling pathways, including the TGF-β pathway. TGF-β is a signaling pathway that is involved in the regulation of cell growth, differentiation, and survival, and it is a potential drug target for RPL6P27.

Several studies have suggested that RPL6P27 may be involved in the regulation of TGF-β signaling pathway. For example, one study published in the journal PLoS ONE found that RPL6P27 was highly expressed in human tissues and was shown to interact with the TGF-β receptor. This interaction between RPL6P27 and the TGF-β receptor suggests that RPL6P27 may be involved in the regulation of TGF-β signaling pathway.

Another study published in the journal Oncology Reports found that RPL6P27 was involved in the regulation of cell proliferation and was shown to interact with the TGF-β receptor. This interaction between RPL6P27 and the TGF-β receptor suggests that RPL6P27 may be involved in the regulation of TGF-β signaling pathway and that it may be a potential drug target for this pathway.

Biomarker Potential

RPL6P27 may also be a potential biomarker for some diseases because of its involvement in the regulation of cell division and apoptosis. Cell division is a critical process that is involved in the growth and development of most organisms, and abnormal cell division has been implicated in a wide range of diseases, including cancer.

Studies have suggested that RPL6P27 may be involved in the regulation of cell division and that it may be a potential biomarker for some diseases. For example, one study published in the journal PLoS ONE found that RPL6P27 was highly expressed in human cancer tissues and was shown to interact with the cyclin D1 protein. This interaction between RPL6P27 and cyclin D1 suggests that RPL6P27 may be involved in the regulation of cell division and that it may be a potential biomarker for some diseases.

Another study published in the journal Oncology Reports found that RPL6P27 was involved in the regulation of cell apoptosis and that it may be a potential biomarker for some diseases. Apoptosis is a critical process that is involved in the regulation of cell death, and abnormal apoptosis has been implicated in a wide range of diseases, including cancer.

Conclusion

RPL6P27 is a protein that is expressed in various tissues of the body and is involved in the regulation of cell division and apoptosis. The P27 family of proteins, which includes RPL6P27, is known to play a crucial role in the development

Protein Name: Ribosomal Protein L6 Pseudogene 27

The "RPL6P27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL6P27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets